Ignore molecular oncology at your peril

Parikh, PM; Prabhash, Kumar; Bhattacharyya, G.S.; Sirohi, Bhawna; Rajappa, Senthill J; Verma, Amit Kumar; Raja, T

doi:10.4103/0019-509x.138258

“…The therapy of lung cancer had evolved from the one-size-fits-all therapy used in the previous decade when all patients with NSCLC with a good performance status were treated with first-line platinum-based doublet chemotherapy to an exquisitely tailored approach. [ 35 36 ] The decision regarding the type of chemotherapy is now based on the type of NSCLC, i.e., patients with adenocarcinoma histology are preferentially treated with a pemetrexed-based regimen. Scagliotti et al .…”

Section: Therapy Of Lung Cancermentioning

confidence: 99%

Lung cancer in the Indian subcontinent

Noronha

¹

,

Pinninti

²

,

Patil

³

et al. 2016

South Asian J Cancer

View full text Add to dashboard Cite

Smoking tobacco, both cigarettes and beedis, is the principal risk factor for causation of lung cancer in Indian men; however, among Indian women, the association with smoking is not strong, suggesting that there could be other risk factors besides smoking. Despite numerous advances in recent years in terms of diagnostic methods, molecular changes, and therapeutic interventions, the outcomes of the lung cancer patients remain poor; hence, a better understanding of the risk factors may impact the preventive measures to be implemented at the community level. There is a lack of comprehensive data on lung cancer in India. In this review, we attempt to collate the available data on lung cancer from India.

show abstract

“…Incorporating strategies to design metronomic chemotherapy trial, with biomarkers and reliable surrogate markers of clinical benefit, will enable oncologists to optimize its value in the current era of personalized medicine. [ 16 17 18 ]…”

mentioning

confidence: 99%

Selected current data on metronomic therapy (and its promise) from India

Parikh

¹

,

Hingmire

²

,

Deshmukh

³

2016

South Asian J Cancer

View full text Add to dashboard Cite

show abstract

“…Incorporating strategies to design metronomic chemotherapy trial, with biomarkers and reliable surrogate markers of clinical benefit, will enable oncologists to optimize its value in the current era of personalized medicine. [16][17][18]…”

Section: Robert S Kerbelmentioning

confidence: 99%